Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
CHICAGO Takeda Pharmaceutical has awarded consumer advertising duties for a prescription sleep medication to independent Cramer-Krasselt, the company confirmed.
Billings for the launch of Ramelteon (which is awaiting final approval from the U.S. Food and Drug Administration) could not be determined. Competitor Ambien spends approximately $60 million annually on ads.
C-K here will share the Ramelteon business with independent Abelson Taylor, which handles industry marketing.
Takeda North America, a Lincolnshire, Ill.-based division of Japan’s largest pharmaceutical concern, filed an application with the FDA for Ramelteon in Setpember and expects to have an answer by the fall.
A
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in